Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial
Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs....
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-01-01
|
| Series: | JCSM Rapid Communications |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rco2.72 |
| _version_ | 1797813608768339968 |
|---|---|
| author | Laura E. Flores Kristen M. Beavers Daniel P. Beavers Katelyn A. Greene Diana A. Madrid Ryan M. Miller Jamy D. Ard Laura D. Bilek Ashley A. Weaver |
| author_facet | Laura E. Flores Kristen M. Beavers Daniel P. Beavers Katelyn A. Greene Diana A. Madrid Ryan M. Miller Jamy D. Ard Laura D. Bilek Ashley A. Weaver |
| author_sort | Laura E. Flores |
| collection | DOAJ |
| description | Abstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs. placebo) on change in dual‐energy x‐ray absorptiometry (DXA)‐ and computed tomography (CT)‐derived lean mass metrics in the year following SG. Methods Twenty‐four SG patients were randomized to 6 months of 150‐mg oral risedronate or placebo capsules (NCT03411902). Body composition was assessed at baseline and 6 months with optional 12‐month follow‐up using whole‐body DXA and CT at the lumbar spine and mid‐thigh. Group treatment effects and 95% confidence intervals (CIs) were generated from a mixed model using contrast statements at 6 and 12 months, adjusted for baseline values. Results Of 24 participants enrolled [55.7 ± 6.7 years (mean ± SD), 79% Caucasian, 83% women, body mass index (BMI) 44.7 ± 6.3 kg/m2], 21 returned for 6‐month testing and 14 returned for 12‐month testing. Six‐month weight loss was −16.3 kg (−20.0, −12.5) and −20.9 kg (−23.7, −18.1) in the risedronate and placebo groups, respectively (P = 0.057). Primary analysis at 6 months revealed a non‐significant sparing of appendicular lean mass in the risedronate group compared with placebo [−1.2 kg (−2.3, −0.1) vs. −2.1 kg (−3.0, −1.2)]; P = 0.20. By 12 months, the risedronate group displayed no change in appendicular lean mass from baseline [−0.5 kg (−1.5, 0.6)]; however, the placebo group experienced significantly augmented loss [−2.9 kg (−3.6, −2.1)]. Conclusions Pilot data indicate that risedronate treatment may mitigate appendicular lean mass loss following SG. Further study is warranted. |
| first_indexed | 2024-03-13T07:54:16Z |
| format | Article |
| id | doaj.art-a151087585d14d708d82d3c79878e61d |
| institution | Directory Open Access Journal |
| issn | 2617-1619 |
| language | English |
| last_indexed | 2024-03-13T07:54:16Z |
| publishDate | 2023-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | JCSM Rapid Communications |
| spelling | doaj.art-a151087585d14d708d82d3c79878e61d2023-06-02T06:45:39ZengWileyJCSM Rapid Communications2617-16192023-01-0161182510.1002/rco2.72Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trialLaura E. Flores0Kristen M. Beavers1Daniel P. Beavers2Katelyn A. Greene3Diana A. Madrid4Ryan M. Miller5Jamy D. Ard6Laura D. Bilek7Ashley A. Weaver8College of Allied Health Professions University of Nebraska Medical Center Omaha NE USADepartment of Health and Exercise Science Wake Forest University Winston‐Salem NC USADepartment of Biostatistics and Data Science Wake Forest School of Medicine Winston‐Salem NC USADepartment of Biomedical Engineering Wake Forest School of Medicine Winston‐Salem NC USADepartment of Biomedical Engineering Wake Forest School of Medicine Winston‐Salem NC USADepartment of Internal Medicine Wake Forest School of Medicine Winston‐Salem NC USADepartment of Bariatric and Weight Management Center Wake Forest School of Medicine Winston‐Salem NC USACollege of Allied Health Professions University of Nebraska Medical Center Omaha NE USADepartment of Biomedical Engineering Wake Forest School of Medicine Winston‐Salem NC USAAbstract Background Despite robust weight loss and cardiometabolic benefit, lean mass loss following sleeve gastrectomy (SG) confers health risk. Bisphosphonates are a potential therapeutic agent for lean mass maintenance. Thus, our objective was to explore the effect of 6 months of risedronate (vs. placebo) on change in dual‐energy x‐ray absorptiometry (DXA)‐ and computed tomography (CT)‐derived lean mass metrics in the year following SG. Methods Twenty‐four SG patients were randomized to 6 months of 150‐mg oral risedronate or placebo capsules (NCT03411902). Body composition was assessed at baseline and 6 months with optional 12‐month follow‐up using whole‐body DXA and CT at the lumbar spine and mid‐thigh. Group treatment effects and 95% confidence intervals (CIs) were generated from a mixed model using contrast statements at 6 and 12 months, adjusted for baseline values. Results Of 24 participants enrolled [55.7 ± 6.7 years (mean ± SD), 79% Caucasian, 83% women, body mass index (BMI) 44.7 ± 6.3 kg/m2], 21 returned for 6‐month testing and 14 returned for 12‐month testing. Six‐month weight loss was −16.3 kg (−20.0, −12.5) and −20.9 kg (−23.7, −18.1) in the risedronate and placebo groups, respectively (P = 0.057). Primary analysis at 6 months revealed a non‐significant sparing of appendicular lean mass in the risedronate group compared with placebo [−1.2 kg (−2.3, −0.1) vs. −2.1 kg (−3.0, −1.2)]; P = 0.20. By 12 months, the risedronate group displayed no change in appendicular lean mass from baseline [−0.5 kg (−1.5, 0.6)]; however, the placebo group experienced significantly augmented loss [−2.9 kg (−3.6, −2.1)]. Conclusions Pilot data indicate that risedronate treatment may mitigate appendicular lean mass loss following SG. Further study is warranted.https://doi.org/10.1002/rco2.72AntiresorptiveBariatric surgeryBody compositionClinical trialsDual‐energy x‐ray absorptiometryLean mass |
| spellingShingle | Laura E. Flores Kristen M. Beavers Daniel P. Beavers Katelyn A. Greene Diana A. Madrid Ryan M. Miller Jamy D. Ard Laura D. Bilek Ashley A. Weaver Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial JCSM Rapid Communications Antiresorptive Bariatric surgery Body composition Clinical trials Dual‐energy x‐ray absorptiometry Lean mass |
| title | Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial |
| title_full | Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial |
| title_fullStr | Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial |
| title_full_unstemmed | Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial |
| title_short | Risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy: results from a pilot randomized controlled trial |
| title_sort | risedronate use may blunt appendicular lean mass loss secondary to sleeve gastrectomy results from a pilot randomized controlled trial |
| topic | Antiresorptive Bariatric surgery Body composition Clinical trials Dual‐energy x‐ray absorptiometry Lean mass |
| url | https://doi.org/10.1002/rco2.72 |
| work_keys_str_mv | AT lauraeflores risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT kristenmbeavers risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT danielpbeavers risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT katelynagreene risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT dianaamadrid risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT ryanmmiller risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT jamydard risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT lauradbilek risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial AT ashleyaweaver risedronateusemaybluntappendicularleanmasslosssecondarytosleevegastrectomyresultsfromapilotrandomizedcontrolledtrial |